Toward Safer Floxuridine Dosing in an Era of Resurgent Hepatic Artery Infusion Pump Chemotherapy
- PMID: 41057748
- DOI: 10.1245/s10434-025-18442-y
Toward Safer Floxuridine Dosing in an Era of Resurgent Hepatic Artery Infusion Pump Chemotherapy
Conflict of interest statement
Disclosure: There are no conflicts of interest.
References
-
- Labadie KP, Fan D, Dominguez DA, et al. Reduced floxuridine dose limits hepatobiliary toxicity without negatively impacting survival after resection of colorectal cancer liver metastases. Ann Surg Oncol. 2025;20:25.
-
- Schwantes IR, Patel RK, Kardosh A, et al. A modified floxuridine reduced-dose protocol for patients with unresectable colorectal liver metastases treated with hepatic arterial infusion. Ann Surg Oncol. 2024;31:6537–45. https://doi.org/10.1245/s10434-024-15729-4 . - DOI - PubMed
-
- Thiels CA, D’Angelica MI. Hepatic artery infusion pumps. J Surg Oncol. 2020;122:70–7. https://doi.org/10.1002/jso.25913 . - DOI - PubMed - PMC
-
- Jarnagin W, Belghiti J, Blumgart LH. Blumgart’s Surgery of the Liver, Biliary Tract, and Pancreas. 5th ed. vol 1. Elsevier Saunders, London, UK, 2012.
-
- Ito K, Ito H, Kemeny NE, et al. Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors. Ann Surg Oncol. 2012;19:1609–17. https://doi.org/10.1245/s10434-011-2102-8 . - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources